Repository logo
 
Publication

New therapeutic approaches on chronic kidney disease

2017Conference object Restricted access
Simple item page
dc.contributor.authorNogueira, A.
dc.contributor.authorVala, Helena
dc.contributor.authorNóbrega, Carmen
dc.contributor.authorPires, C. A.
dc.contributor.authorColaço, B.
dc.contributor.authorOliveira, P. A.
dc.contributor.authorPires, M. J.
dc.date.accessioned2017-11-29T13:29:56Z
dc.date.available2017-11-29T13:29:56Z
dc.date.issued2017
dc.description.abstractIntroduction: chronic kidney disease is a serious public health problem that affects millions of patients worldwide. So, the main research goals in the CKD patients are the research of new therapeutic approaches capable of slowing down the progression to end-stage renal disease. Objective: the aim of this work, was to evaluate the effects of chronic administration of chaetomellic acid A (CAA), which selectively blocks H-Ras farnesylation, on kidney chronic lesions in 5/6 nephrectomized Wistar rats, an animal model of chronic renal disease. Material and methods: sixty male Wistar rats (Rattus norvergicus) were housed under controlled conditions. After seven weeks of acclimatization, rats (weighing 359 to 402 g) were sham-operated (SO) or submitted to 5/6 nephrectomy (RMR). One week after surgery surviving animals (n=53) were distributed into four groups: SO: SO rats receiving no treatment (n=13); SO+CAA: SO rats receiving CAA treatment (n=13); RMR: RMR rats receiving no treatment (n=14); RMR+CAA: RMR rats receiving CAA treatment (n=13). CAA was intraperitoneally administered (0.23 µg/Kg) three times a week for six months. Six months after the surgical procedure, in the left kidney of each animal was evaluated the mean cortical and medullary echogenicity by two-dimensional ultrasonography. Then, the kidneys were removed, fixed in 10% neutral-buffered formalin and processed for routine histopathological diagnosis and chronic lesions were evaluated, by Hematoxylin-Eosin, reticulin and Masson trichrome methods, for severity. All experimental procedures followed the European (European Directive 2010/63/EU) and National (Decree-Law 113/2013) legislation on the protection of the animals used for scientific purposes. Results: the kidneys of the RMR animals treated with CAA showed a significantly decrease in the medullary echogenicity (p<0.05) compared with the RMR rats that received no treatment. Glomerulosclerosis and arteriolosclerosis scores were significantly lower (p<0.001) in the RMR+CAA group when compared with the RMR group. There were no significant differences in interstitial fibrosis, interstitial inflammation and tubular dilatation scores between the RMR+CAA and RMR groups.Conclusion: this data suggests that pharmacological inhibition of H-Ras proteins activation may be a future strategy in the prevention of end-stage renal disease.pt_PT
dc.description.sponsorshipThis work is financed by national funds through FCT - Fundação para a Ciência e Tecnologia, I.P., under the project UID/Multi/04016/2016. Furthermore we would like to thank the Instituto Politécnico de Viseu, CI&DETS for their support and FCT, FCOMP-01-0124-FEDER-009525; IPV, CI&DETS, FCT and QREN/FEDER (Ovislab ICT-2013-05-004-5314 ID-64757). This work is supported by European Investment Funds by FEDER/COMPETE/POCI– Operacional Competitiveness and Internacionalization Programme, under Project POCI-01-0145-FEDER-006958 and National Funds by FCT - Portuguese Foundation for Science and Technology, under the project UID/AGR/04033/2013. Furthermore we would like to thank to UTAD and CITABS for their support.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationNogueira, A., Vala, H., Nóbrega, C., Pires, C.A., Esteves, F., Colaço, B., Oliveira, P.A., & Pires,M.J. (Agosto/Setembro, 2017). New therapeutic approaches on chronic kidney disease (pp. 51-52). In Abstract book of the Cutting Edge Pathology, 3rd Joint European Congress of the ESVP, ESTP and ECVP, Lyon, France.pt_PT
dc.identifier.urihttp://hdl.handle.net/10400.19/4727
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.relationThis work is financed by national funds through FCT - Fundação para a Ciência e Tecnologia, I.P., under the project UID/Multi/04016/2016. Furthermore we would like to thank the Instituto Politécnico de Viseu, CI&DETS for their support and FCT, FCOMP-01-0124-FEDER-009525; IPV, CI&DETS, FCT and QREN/FEDER (Ovislab ICT-2013-05-004-5314 ID-64757). This work is supported by European Investment Funds by FEDER/COMPETE/POCI– Operacional Competitiveness and Internacionalization Programme, under Project POCI-01-0145-FEDER-006958 and National Funds by FCT - Portuguese Foundation for Science and Technology, under the project UID/AGR/04033/2013. Furthermore we would like to thank to UTAD and CITABS for their support.pt_PT
dc.subjectChronic kidney diseasept_PT
dc.subjectNew therapeutic approachespt_PT
dc.subjectChaetomellic acid A (CAA)pt_PT
dc.titleNew therapeutic approaches on chronic kidney diseasept_PT
dc.typeconference object
dspace.entity.typePublication
oaire.citation.conferencePlaceLyon, Francept_PT
oaire.citation.endPage52pt_PT
oaire.citation.startPage51pt_PT
oaire.citation.titleCutting Edge Pathologypt_PT
person.familyNameVala Correia
person.familyNameNóbrega
person.givenNameHelena Maria
person.givenNameCarmen
person.identifier.ciencia-id7A1E-E85E-FFA4
person.identifier.ciencia-idD51F-A1CF-C925
person.identifier.orcid0000-0001-6829-4867
person.identifier.orcid0000-0003-3941-799X
rcaap.rightsrestrictedAccesspt_PT
rcaap.typeconferenceObjectpt_PT
relation.isAuthorOfPublicationcdc3d2e2-df06-40ed-8900-1ecbc8a06c8a
relation.isAuthorOfPublication0b9969e9-920a-4572-8fb1-73abb2fa3988
relation.isAuthorOfPublication.latestForDiscovery0b9969e9-920a-4572-8fb1-73abb2fa3988

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
39 Abstract New therapeutic approaches on CKD ESVP p 51 52 17 (1).pdf
Size:
37.01 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.79 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

ESAV - DZERV - Resumos de eventos científicos não indexados à WoS/Scopus